Recombinant African swine fever bivalent vaccine
By designing a recombinant bivalent African swine fever vaccine that integrates nucleocapsid proteins and epitope proteins expressing African swine fever type II and type I viruses, the problem of incomplete neutralizing antibody response in existing vaccines has been solved, achieving a highly efficient humoral and cellular immune response and enhancing the prevention and control of African swine fever.
Patent Information
- Application Number
- CN202410766942.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-14
- Publication Date
- 2024-11-08
AI Technical Summary
Existing African swine fever virus vaccines exhibit persistent non-neutralization when inducing neutralizing antibody responses, leading to persistent infection in pig herds. Furthermore, the distribution and mutation of different viral genotypes increase the difficulty of prevention and control, and existing vaccines are unable to effectively elicit humoral and cellular immune responses.
A recombinant bivalent African swine fever vaccine was designed by cloning the gene encoding a fusion protein of the nucleocapsid protein of the classic African swine fever type II strain and the epidemic type I strain into a vector, expressing and purifying the fusion protein to induce a high level of humoral and cellular immune response.
This vaccine can significantly increase antibody titers and cellular immune responses in animals, induce high levels of IgG production, enhance cytokine transcription and cell proliferation, and provide an effective protective immune response.
Smart Images

Figure CN118909135A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology and genetic engineering, and mainly relates to the preparation and application of a recombinant African swine fever bivalent vaccine. Specifically, by using gene recombination technology, the common sequence of the nucleocapsid protein pB646L of the African swine fever type II classical strain and the African swine fever virus type I epidemic strain and the fusion protein encoding gene of the B cell epitope and T cell epitope of pCP204L, pE183L, pPK78R, pA104R are cloned into a vector, the host bacteria are transformed, and after fermentation, purification, mixed preparation and other processes, a recombinant African swine fever bivalent vaccine and the application of the vaccine in preventing African swine fever are obtained. Background Art
[0002] After the African swine fever virus was introduced into my country in 2018, it continued to spread throughout the country. In recent years, the emergence of two mutant viruses, the low-virulence strain of genotype II and the genotype I African swine fever virus, has made the pig farming industry even worse. There are genetic differences between genotype I and II African swine fever viruses. The genotype I virus has diversity in its gene sequence, while the genotype II is relatively conservative. Genotype I African swine fever is mainly prevalent in the African continent, especially in southern and eastern countries. Genotype II is widely distributed in Eurasia, including Asia and Europe. The distribution areas of different genotypes also reflect the geographical transmission pattern and prevalence of the virus. In January 2021, researchers reported that genotype I African swine fever virus was isolated in Shandong and Henan respectively. Both strains were low-virulence strains, and their gene sequences were highly homologous to the NH / P68 (Portugal 1968) strain after sequencing. Since then, researchers have discovered three special isolates from Jiangsu, Henan and Inner Mongolia. Based on the B646L gene sequence, they identified the three isolates as genotype I. These viruses are all HAD-positive, while the previously discovered genotype I viruses are all HAD-negative. Further sequencing found that the B646L gene and EP402R gene of these newly emerged viruses came from genotype I viruses (43.5%) and genotype II viruses (56.5%), respectively. That is, the new virus is a recombinant virus of two genotype viruses. The three newly emerged viruses have 99.97-99.99% homology with each other at the nucleotide level and form a unique branch on the phylogenetic tree, which clusters between genotype I and II viruses. At the same time, new reassortants between genotype II strong and weak viruses and genotype I weak viruses may subsequently appear. Therefore, the emergence of genotype I ASFV will bring more problems and greater challenges to ASF eradication in China.
[0003] The pathogen of ASF is African swine fever virus (ASFV), an enveloped double-stranded DNA virus that can cause systemic hemorrhagic disease in domestic pigs. ASFV is the only member of the genus ASFV in the family Asfrigiviridae and is currently the only insect-borne DNA virus.
[0004] ASFV is a double-enveloped virus. The viral genome is a linear double-stranded DNA, including a stable region in the middle and variable regions at both ends. It is 170-190 kbp in size and encodes 150-167 open reading frames. The ASFV virus particle is an icosahedral multilayer structure with a diameter of about 250 nm. From the outside to the inside, there are the outer viral envelope, capsid, inner membrane, inner core shell and viral genome. The movement of the virus in the process of entering and exiting the host cell depends on the cytoskeleton, which is usually reorganized throughout the infection process. ASFV encodes about 200 proteins, of which more than 50 are structural proteins, which perform a variety of functions including maintaining the morphology of viral particles, adsorption, invasion of host cells, affecting the functions of multiple factors in host cells, and regulating the defense mechanisms of host cells such as autophagy, apoptosis and inflammatory response. There are many ASFV replication-related genes and expressed proteins, such as p72, p30 and other proteins, which are essential components in the ASFV virus replication process. Histone-like proteins pA104R, p10 (K78R), pG1340L, pD1133L, pB962L, pQ706L, etc. are also related to the virus replication, transcription initiation and other processes.
[0005] Studies have shown that there is still a contradictory trend in the understanding of the role of neutralizing antibodies in protection against ASFV. In the process of in vitro neutralization tests using the sera of most recovered pigs, researchers found persistent non-neutralizing viruses accounting for about 10% of the total amount of virus. This part of persistent non-neutralizing virus may be the reason for the common ASFV persistent infection in pigs, and infectious virus still exists even in the presence of excessive neutralizing antibodies. In other virus models, the existence of this part of persistent non-neutralizing virus has been attributed to the following points: the formation of virus aggregates that cannot be captured by antibodies; the inability of serum to neutralize a large number of virus particles, and the low titer antiserum produces neutralization-resistant mutant strains; the low affinity of neutralizing antibodies requires long incubation to achieve effective neutralization; the antibody-virus complex has low stability and is easy to dissociate after dilution; and the presence of blocking antibodies that inhibit virus neutralization. Most of the above hypotheses have been studied in ASF, and the experiments used sera from recovered pigs infected with attenuated strains, which have complete or incomplete virus neutralization ability. Experiments have shown that incomplete neutralization of ASFV may be caused by virus aggregation rather than low affinity or low stability of virus-antibody complexes.
[0006] Attempts to purify antigenically mutated viruses from persistently non-neutralizing ASFV viruses were also unsuccessful. Competition experiments between sera showed that sera that exhibit persistent non-neutralization blocked complete neutralization (100%) mediated by another serum. These results strongly suggest that blocking antibodies induced during ASFV infection may be one of the main reasons for the presence of persistent non-neutralizing viruses in neutralization assays and may also explain why persistent infection occurs in recovered pigs. Other factors associated with viral infection, such as direct cell-to-cell viral transmission, cannot be ignored, which can affect the amount of virus neutralized by antibody. Strong neutralizing antibody responses are associated with protection, but are not absolute, as protection can be achieved in the absence of neutralizing antibodies. In addition, another study showed that the presence of neutralizing antibodies is not necessary for protection. A study by Oura and colleagues showed that CD8+ T cells play an important role in ASFV protection, with a clear correlation between this protection and the presence of ASFV-specific T. Natural killer (NK) cells also appear to play a protective role. After pigs are immunized with a naturally attenuated NH / P68 strain that has no hematopoietic adsorption activity, they produce high levels of NK cell activity that can resist attacks by strong strains.
[0007] As an ideal immunogen, the antigen molecule can contain both the target antigen B cell epitopes and self or exogenous T cell epitopes, which can induce highly specific humoral or cellular immune responses, play a preventive or therapeutic role at the humoral and cellular immunity levels, and thus can confer a wider range of protection. The immunogenicity of the antigen can be enhanced by designing epitopes hidden inside the antigen molecule. Pan-DR helper T cell epitopes (PADRE) or universal T epitopes (genetically permissive epitopes) bind to common HLA-DR molecules in the population with high affinity and are less restricted by MHC. The R&D center first identified the high coverage areas of MHC-II and then ranked them according to their MHC-I coverage. For antigen sequences with high scores, candidate antigens with 90% sequence similarity were further searched on the GENBANK database to assess whether any candidate antigens had ever been used as T cell epitopes. Among the common MHC alleles of the host, the HLA-C gene has a wider range of antigen epitope presentation capabilities, so the development of vaccines based on antigen epitopes should include antigen epitopes related to HLA-C. The T cell epitopes used in the design can be transferred to the cell surface by binding complexes with MHC class I molecules and recognized by the TCR of CD8+ cytotoxic T cells, and can also be combined with MHC class II molecules to form complexes and transported to the cell surface and recognized by the TCR of CD4+ T cells. Summary of the invention
[0008] The present invention clones the common sequence of the nucleocapsid protein pB646L of the African swine fever type II classical strain and the African swine fever virus type I epidemic strain and the fusion protein coding genes of the B cell epitopes and T cell epitopes of pCP204L, pE183L, pPK78R, and pA104R into vectors for expression in Escherichia coli, and then obtains a composition with an ideal immune effect through processes such as protein crude extraction, purification, and preparation: a recombinant African swine fever bivalent vaccine. The recombinant African swine fever bivalent vaccine can induce a higher level of humoral immunity and cellular immune response when immunizing target animals.
[0009] One of the objects of the present invention is to provide a recombinant African swine fever bivalent vaccine immune composition that can stimulate humoral immunity and cellular immunity; the second object of the present invention is to provide a method for constructing and obtaining the recombinant African swine fever bivalent vaccine antigen; the third object of the present invention is to provide a genetically engineered strain that can express the recombinant African swine fever bivalent vaccine antigen; the fourth object of the present invention is to provide a method for preparing the recombinant African swine fever bivalent vaccine; the fifth object of the present invention is to provide the use of the recombinant African swine fever bivalent vaccine in vaccine formulation and animal immunization.
[0010] In the first aspect, the present invention provides a recombinant African swine fever bivalent vaccine polypeptide and its composition. It contains a fusion protein or polypeptide of the common sequence of the nucleocapsid protein pB646L of the African swine fever type II classical strain and the African swine fever virus type I epidemic strain and pCP204L, pE183L, pPK78R, pA104R B cell epitopes and T cell epitopes. The series connection can be carried out by genetic engineering methods or artificial synthesis. In addition to containing the common sequence of the nucleocapsid protein pB646L of the African swine fever type II classical strain and the African swine fever virus type I epidemic strain and pCP204L, pE183L, pPK78R, pA104R B cell epitopes and T cell epitopes, the recombinant African swine fever bivalent vaccine also contains non-immunologically active substances. The non-immunologically active substances are the connecting parts of each polypeptide, which have no immunogenicity and no adjuvant activity, and mainly include linker peptides, chemically modified parts, N-terminal signal peptides and C-terminal polyadenylic acid. The pharmaceutically acceptable salts are salts that are non-toxic, non-irritating and non-allergenic and are suitable for human or animal tissues. Inactive substances and pharmaceutically acceptable salts are well known to those skilled in the art.
[0011] Therefore, the amino acid sequence of the recombinant African swine fever bivalent vaccine ASFVI / II polypeptide is as follows: SARIYAGQGYTEHQAQHIEQYGKAPDFNKVIGGKPYVPIGFEYNKVRPHTGTPTLGNKGGMHKPHQSKPILTDENDTQRTCTHTNPKFLSQHFPENSHNIQTAGKQDITPITDATYLGSGGGAFCLIANDGKADGGIKNVNKSYGKPDGGERL YENVRFDVNGNGGVTTLVRKFCIPGDGGENSHNIQTAGKQDPITDATYLDIRRNGSGTDENDTQRTCSHTNPGGSCNGPQTPKYYQPPLGIAGRPSRRNIRFKPWGDIPGCKVVTVKAKPARQGHNPAGSGRGHTGKTHAGGRSRGIPIYQN GSRLTKSELEKKGSGQYTEQQHENNTFFMPQKNSFNESYNPYQWGSGQVVFHAGSLYNWFSVEIINSGRITVKYDGSGFFQPVYPRHYGECLSPVTTPGGASVGKPVTGRPATNRPATNKCAAYPIQYLKEDSRDRTSGSGVNIARSRGIPIY QNGGFILNISMKMEVIFKTDLRAGSGECLSPVTTPSFFSTGGAIEEEDIQFICAAYIQYLKEDSRDRTSIGSLEYDENADTGSGRGIPIYQNGSRLTKSELEGSGLESNHETNGHKADSHETNECTSSFETLFEQGSGKKAAAIEEEDIQFINP In the second aspect, the present invention provides a nucleotide molecule encoding the two recombinant African swine fever bivalent vaccine polypeptides described in the first aspect of the present invention. In the present invention, the nucleotide can be in the form of RNA or DNA, and the tandem sequence is synthesized by artificial synthesis, and then cloned into a vector after genetic engineering operation, transformed into Escherichia coli, screened, fermented, and purified to obtain the recombinant African swine fever bivalent vaccine polypeptide. In the present invention, the nucleic acid can be subjected to conventional molecular biological operations, such as: PCR, restriction endonuclease digestion, connection, etc., and restriction sites are added to both the 5' end and the 3' end of the nucleic acid design. Preferably, the ASFVI / II encoding nucleotide sequence in the present invention is as follows: agc gcg cgc att tat gcg ggc cag ggc tat acc gaa cat cag gcg cag catatt gaa cag tat ggc aaa gcg ccg gat ttt aac aaa gtg att ggc ggc aaa ccg tatgtg ccg att ggc ttt gaa tat aac aaa gtg cgc ccg cat acc ggc acc ccg acc ctgggc aac aaa ggc ggc atg cat aaa ccg cat cag agc aaa ccg att ctg acc gat gaaaaac gat acc cag cgc acc tgc acc cat acc aac ccg aaa ttt ctg agc cag cat tttccg gaa aac agc cat aac att cag acc gcg ggc aaa cag gat att acc ccg att accgat gcg acc tat ctg ggc agc ggc ggc gcg ggc gcg ttt tgc ctg att gcg aac gat ggcaaa gcg gat ggc ggc att aaa aac gtg aaa aagc tat ggc aaa ccg gat ggc ggcgaa cgc ctg tat gaa aac gtg cgc ttt gat gtg aac ggc aac ggc ggc gtg acc accctg gtg cgc aaa ttt tgc att ccg ggc gat ggc ggc gaa aac agc cat aac att cagacc gcg ggc aaa cag gat ccg att acc gat gcg acc tat ctg gat att cgc cgc aacggc agc ggc acc gat gaa aac gat acc cag cgc acc tgc agc cat acc aac ccg ggcggc agc tgc aac ggc ccg cag acc ccg aaa tat tat cag ccg ctg ggc ggc attgcg ggc cgc ccg aagc cgc cgc aacatt cgc ttt aaa ccg tgg ggc gat att ccg ggctgc aaa gtg gtg acc gtg aaa gcg aaa ccg gcg cgc cag ggc cat aac ccg gcg ggcagc ggc cgc ggc cat acc ggc aaa acc cat gcg ggc ggc cgc agc cgc ggc att ccgatt tat cag aac ggc agc cgc ctg acc aaa agc gaa ctg gaa aaa aaa ggc agc ggccag tat acc gaa cag cag cat gaa aac aac acc ttt ttt atg ccg cag aaa aac agcttt aac gaa agc tat aac ccg tat cag tgg ggc agc ggc cag gtg gtg ttt cat gcgggc agc ctg tat aac tgg ttt agc gtg gaa att aac agc ggc cgc att acc gtgaaa tat gat ggc agc ggc ttt ttt cag ccg gtg tat ccgc cat tat ggc gaa tgcctg agc ccg gtg acc acc ccg ggc ggc gcg agc gtg ggc aaa ccg gtg acc ggc cgcccg gcg acc aac cgc ccg gcg acc aac aaa tgc gcg gcg tat ccg att cag tat ctgaaa gaa gat agc cgc gat cgc acc agc ggc agc ggc gtg aac att gcg cgc agc cgcggc att ccg att tat cag aac ggc ggc ttt at ctg aac att aagc atg aaa atg gaagtg atttt aaa acc gat ctg cgc gcg ggc agc ggc gaa tgc ctg agc ccg gtg accacc ccg agc ttt ttt agc acc ggc ggc gcg att gaagat att cag ttt atttgc gcg gcg tat att cag tat ctg aaa gaa gat agc cgc gat cgc acc agc att ggcagc ctg gaa tat gat gaa aac gcg gat acc ggc agc ggc cgc ggc att ccg att tatcag aac ggc agc cgc ctg acc aaa agc gaa ctg gaa ggc agc ggc ctg gaa agc aaccat gaa acc aac ggc cat aaa gcg gat agc cat gaa acc aac gaa tgc acc agc agcttt gaa acc ctg ttt gaa cag ggc agc ggc aaa aaa gcg gcg gcg att gaa gaa gaagat att cag ttt att aac ccg In the third aspect, the present invention provides a vector, which contains, in addition to the nucleotide molecule encoding the recombinant African swine fever bivalent vaccine described in the second aspect of the present invention, an expression control element operably linked to the nucleotide sequence and required for expression (transcription and translation) in prokaryotic cells. The most basic expression control elements include promoters, transcription terminators, enhancers, selectable markers, etc. These regulatory elements are well known in the art.
[0012] In a fourth aspect, the present invention provides a host cell containing the vector described in the third aspect of the present invention. The host cell is transformed or transfected with the gene sequence encoding the protein described in the present invention, and then tested to have good genetic and expression stability, and can be used for fermentation expression and production of the required recombinant African swine fever bivalent vaccine antigen. In the present invention, Escherichia coli BL21 (DE3, Plys) is preferably used as the host bacteria for the expression of the target protein.
[0013] In the fifth aspect, the present invention provides a method for preparing a recombinant African swine fever bivalent vaccine, which comprises the following steps: fermenting an engineered bacterium to express an ASFVI / II fusion protein, and obtaining the desired recombinant African swine fever bivalent vaccine through a crude purification, a fine purification process, and a subsequent mixed preparation process. The methods involved include but are not limited to bacterial cell crushing, inclusion body washing, centrifugation, denaturation, affinity chromatography, hydrophobic chromatography, anion exchange chromatography, reverse phase chromatography, renaturation, and the like.
[0014] In a sixth aspect, the present invention provides a recombinant African swine fever bivalent vaccine, which comprises the polypeptide composition described in the first aspect of the present invention and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier described in the present invention is an oil adjuvant, a water adjuvant, and the like.
[0015] In the seventh aspect, the present invention provides the use of the recombinant African swine fever bivalent vaccine described in the sixth aspect. The recombinant African swine fever bivalent vaccine can produce sufficiently effective humoral immunity and cellular immune response (see Examples 5, 6, 7, 8, 9, 10, and 11) by intramuscular injection, intradermal or subcutaneous injection, and aerosol inoculation of animals at a certain effective dose, stimulate the production of higher IgG levels, induce peripheral blood T lymphocyte proliferation, enhance cytokine transcription, and increase cytokine production. In addition, in an embodiment of the present invention, the recombinant African swine fever bivalent vaccine described in the present invention is safe by conducting laboratory safety tests on the vaccine (see Example 4).
[0016] In addition, it should be pointed out that, based on the disclosure of the context of this application, other aspects of the present invention with substantial characteristics are obvious to a person of ordinary skill in the art. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] The following drawings are used to illustrate specific embodiments of the present invention and are not used to limit the scope of the present invention defined by the claims. Figure 1 This is the construction diagram of the recombinant African swine fever bivalent vaccine expression plasmid pRSETA-ASFVI / II; Figure 2 The figure is the restriction enzyme digestion diagram of the vector plasmid, where lane 1 is a DNA marker, and the molecular weights from top to bottom are 5000bp, 3000bp, 2000bp, 1000bp, 750bp, 500bp, 250bp, and 100bp, lane 2 is a blank control, lane 3 is a complete plasmid pRSETA-ASFVI / II sample, and lanes 4 and 5 are pRSETA-ASFVI / II restriction enzyme digestion samples; Figure 3 It is an SDS-PAGE detection diagram, where lane 1 is the protein marker, from top to bottom, 116KDa, 66.2KDa, 45KDa, 35KDa, 25KDa, 18.4KDa, 14.4KDa, lane 2 is the pRSETA-ASFVI / II / BL21 (DE3, Plys) uninduced control sample, lane 3 is the pRSETA-ASFVI / II / BL21 (DE3, Plys) induced sample, and the arrows point to the expressed target protein; Figure 4It is the Western-blot test result of recombinant African swine fever bivalent vaccine ASFVI / II antigen protein, where lane 1 is protein pre-stained Marker, from top to bottom are 180KDa, 135 KDa, 100 KDa, 75 KDa, 63 KDa, 45KDa, 35KDa, 25KDa, 17KDa, 11KDa, lane 2 is purified ASFVI / II antigen protein, and lane 3 is negative control; Figure 5 It is the SDS-PAGE test result of the recombinant African swine fever bivalent vaccine ASFVI / II antigen protein, where lane 1 is the protein marker, from top to bottom, 180KDa, 135 KDa, 100KDa, 75 KDa, 63 KDa, 45KDa, 35KDa, 25KDa, 17KDa, 11KDa, and lane 2 is the purified ASFVI / II antigen protein sample; Figure 6 To detect antibody titer of piglets after immunization; Figure 7 To detect the concentration of IFN gamma in serum; Figure 8 To detect the concentration of cytokine TNF in peripheral blood; Fig. 9 To detect the concentration of cytokine IL-4 in peripheral blood; Fig.10 To detect the concentration of cytokine IL-6 in peripheral blood; Fig.11 To detect the concentration of cytokine IL-10 in peripheral blood; Fig.12 To detect the frequency of IFNgamma-SC production in peripheral blood (type I); Fig.13 To detect the frequency of IFNgamma-SC production in peripheral blood (type II); Fig.14 To detect the mRNA transcription level of cytokine IL-17 in peripheral blood; Fig.15 To detect the mRNA transcription level of cytokine TGF-β in peripheral blood; Fig.16 To detect the mRNA transcription level of cytokine IFN-γ in peripheral blood; Fig.17 It is the change of the proportion of CD3+ subpopulation of T lymphocytes in peripheral blood lymphocytes; Fig.18 It is the change of the proportion of CD3+CD4+ subpopulation of T lymphocytes in peripheral blood lymphocytes; Fig.19 It is the change of the proportion of CD3+CD8+ subsets of T lymphocytes in peripheral blood lymphocytes; Fig. 20 It is the change of CD4+ / CD8+ subpopulation ratio of T lymphocytes in peripheral blood lymphocytes. DETAILED DESCRIPTION
[0018] The specific experimental methods described in the examples are merely exemplary descriptions, which are used to illustrate the present invention in detail, but are not intended to limit the scope of the present invention.
[0019] Example 1 Construction of Escherichia coli expression vector and expression strain 1 The designed polypeptide encoding nucleotides were sent to Shanghai Yingjun Biotechnology Co., Ltd. for synthesis. BamH (5' end) and HindIII (3' end) restriction enzyme site, the fragments were synthesized and cloned into the pMD18T vector, and the sequence determination confirmed that the inserted gene fragment was consistent with the designed sequence. The recombinant plasmid was named pMD18T-ASFVI / II. The plasmid was digested with the corresponding restriction endonuclease. The E. coli expression vector was selected from the pRSETA plasmid of Invitrogen, and the same restriction endonuclease was used for digestion. The digestion conditions were: 10μl reaction system, 2μl plasmid was added to the system, 5 units of restriction endonuclease (New England Biolabs), 1μl of 10× buffer was added, and deionized water was added to make up, and digestion was carried out at 37℃ for 1.5 hours. After the digestion was completed, 1μl 200mM EDTA was added to terminate the reaction. In 1% agarose gel electrophoresis, electrophoresis was performed for 30 minutes. The 2.6Kb pRSETA plasmid and the 1.85Kb ASFVI / II fragment were cut out under ultraviolet light, and gel recovery was performed according to the instructions of the gel recovery kit of Solebo. The polytope nucleotide fragments were mixed with the expression vector in a ratio of 1:2-3 for vector:fragment. The reaction system was 15 μl and ligated with T4 DNA ligase at 16°C overnight. The recombinant plasmids were named pRSETA-ASFVI / II (see Figure 1 ), transformed into competent Escherichia coli BL21 (DE3) pLysS.
[0020] 2 Transformation: Melt pRSETA-ASFVI / II on ice, add 2μl ligation reaction solution respectively, mix again, ice-water bath for 30 minutes, 42℃ for 30 seconds, then quickly return to ice bath for 1.5 minutes, add 1mL LB culture medium, incubate at 37℃ for 1 hour, centrifuge at 4000g for 10 seconds, discard the supernatant, and resuspend the bacteria in 200μl LB culture medium; spread the bacterial solution evenly on LB agar culture plate containing 100μg / mL ampicillin, invert and culture in a 37℃ constant temperature incubator for 12-16 hours until clones are formed.
[0021] 3 Identification: Pick a single clone from the plate and place it in LB medium. Incubate at 37°C, 200 rpm for 12 hours. Extract the plasmid and use the enzymes BamH and HindIII After double enzyme digestion, a clone of 1.85Kb of the corresponding size fragment of ASFVI / II can be cut out, which can be preliminarily determined as a positive clone (see Figure 2 The positive clones were sequenced to further verify their correctness.
[0022] 4 Induce expression. Cultivate the positive clones overnight, transfer at a ratio of 1:100 the next morning, and add 0.2 mM IPTG after 4 hours of cultivation. Continue culturing for 4 hours and prepare samples. Detect the expression of the target protein by conventional SDS-PAGE (see Figure 3 ), the 73.74KDa specific band was found to be the correct clone, and conventional Western-blot was used to further confirm its expression accuracy (see Figure 4 ); Select the correct clone, amplify the culture, and use the selected positive clone as the engineering bacteria to establish the original seed bank. The strain is named pRSETA-ASFVI / II / BL21 (DE3, Plys).
[0023] 1 Fermentation Take the production strain pRSETA-ASFVI / II / BL21 (DE3, Plys) and inoculate it in 5 mL LB liquid culture medium (containing 100μg / mL ampicillin), and activate the strain by shaking culture at 37℃ and 200 rpm for 10 hours. Then inoculate it into a shake flask at an inoculation rate of 1:100, shake culture at 37℃ until OD600=3, and then inoculate it into the fermentation tank at a ratio of 10%. The fermentation medium is a semi-synthetic medium prepared with distilled water. Calibrate the dissolved oxygen and pH electrodes, turn on the tank stirring, the number of revolutions is 300rpm, sterilize the tank online, and when the temperature of the culture solution in the tank drops to 37.0℃, calibrate the pH and dissolved oxygen (OD) zero point. The fermentation temperature was 37.0±0.1°C, the dissolved oxygen was controlled at about 40%, the pH was controlled at 7.0, and 500 mL of feed was added when the culture OD600 was 1.0-1.2 after inoculation. IPTG (final concentration of 0.2 mM) was added 1 hour after feeding to induce expression. The fermentation ended after 4 hours of continuous induction.
[0024] 2 Purification: 100 g of the collected bacteria were suspended with 1000 ml Tris-HCl and then lysed three times with a low-temperature high-pressure homogenizer at 4°C. Inclusion bodies were collected by centrifugation at 4°C, 12,000 rpm for 30 min. The inclusion body precipitate was mixed with 6M guanidine hydrochloride, 0.3% β-ME, and 20mM Tris-cl (pH=8.00), stirred at room temperature for 4 hours, and centrifuged at 8,000 rpm for 30 min. The supernatant was collected and the precipitate was discarded. The inclusion body supernatant was equilibrated with 20mM phosphate buffer at pH=8.0, 0.5M sodium chloride, and 20mM imidazole, and eluted with 20mM phosphate buffer at pH=8.0, 0.5M sodium chloride, and 0.5M imidazole; the recombinant ASFVI / II protein stock solution was obtained, and the semi-finished product stock solution was taken for SDS-PAGE detection (see Figure 5 ).
[0025] 3 Preparation: The purified ASFVI / II fusion protein was sterilized by filtration through a sterile 0.22μm Millipore filter and diluted to 200μg / mL with sterile PBS. The purified ASFVI / II was emulsified with ICTYOLANE 17 adjuvant to prepare a recombinant African swine fever bivalent vaccine for later use.
[0026] 1 Materials 1.1 Vaccine: The emulsion of recombinant African swine fever bivalent vaccine is provided by Qingdao Mingqin Biological Research and Development Center, with batch numbers 202201, 202202, and 202203.
[0027] 1.2 Experimental animals: 17 Balb / C mice weighing 18-22 g, and healthy piglets aged 20-30 days (negative for ASFV, PRRSV, CSFV, and PCV2 antibodies by ELISA, and negative for ASFV, PRRSV, CSFV, and PCV2 antigens by PCR).
[0028] 2 Methods 2.1 Safety of the vaccine in mice 18-22g Balb / C mice, 5 mice were immunized in each batch of vaccine, a total of three batches, 15 mice were immunized, the immunization method was: 0.5ml was injected subcutaneously each, and 5 blank controls were set up at the same time. The health status of the mice was observed for 10 consecutive days.
[0029] 2.2 Safety of vaccines for piglets Select healthy piglets aged 20 to 30 days and use recombinant African swine fever bivalent vaccine, 5 piglets per batch, three batches in total, 15 piglets were immunized. The immunization method is: 2 ml of vaccine was injected intramuscularly behind the ear of each pig, and 5 blank controls were set up at the same time, and clinical observation was carried out for 14 days.
[0030] 3 Results 3.1 Vaccine safety test in mice The results are shown in Table 1. After immunization, the appetite, mental state and health status of all mice were normal, consistent with the blank control group, and no deaths occurred. It can be seen that the recombinant African swine fever bivalent vaccine is safe for mice, see Table 1.
[0031] Table 1 Results of vaccine safety test on mice Group Number of animals body temperature appetite Spirit Health status Number of deaths 202201 5 normal normal normal Good health 0 202202 5 normal normal normal Good health 0 202203 5 normal normal normal Good health 0 Comparison 5 normal normal normal Good health 0 3.2 Vaccine safety test for piglets The results are shown in Table 2. During the 14-day observation period, all immunized piglets had normal body temperature, spirit and appetite, and no clinical abnormalities occurred. After the end of the experiment, all 15 piglets were alive. The 5 piglets in the blank control group also had no adverse reactions. This shows that the recombinant African swine fever bivalent vaccine is safe for piglets.
[0032] Table 2 Results of vaccine safety test on piglets Group Number of animals body temperature appetite Spirit Abnormal conditions Number of deaths 202201 5 heads normal normal normal none 0 202202 5 heads normal normal normal none 0 202203 5 heads normal normal normal none 0 Comparison 5 heads normal normal normal none 0
[0033] 1 Experimental animals 7±1 weeks old healthy piglets with negative antigen and antibody (negative for ASFV, PRRSV, CSFV, PCV2 antibodies detected by ELISA method, and negative for ASFV, PRRSV, CSFV, PCV2 antigens detected by PCR method). The experimental pigs were allowed to adapt to the environment for one week before starting the experiment.
[0034] 2 Vaccines The recombinant African swine fever bivalent vaccine is provided by the R&D center with batch numbers 202201, 202202, and 202203.
[0035] 3 Experimental design 3.1 Grouping and Immunization Healthy piglets were raised in a BSL-3 isolation room for animal immunization and sampling. The animals were randomly divided into 4 groups, 3 vaccine immunization groups and a PBS control group, 5 pigs / group. 2 ml / pig was injected intramuscularly behind the ear. 14 days after immunization, the same immunization method was used for booster immunization.
[0036] 3.2 PBMC and serum separation Blood was collected from the anterior vena cava of all experimental pigs before immunization (0 days), 7 days, 14 days, 21 days, 28 days, 35 days, and 42 days after immunization, with 8 ml of blood collected from each pig. 3 ml of the blood was injected into sterile centrifuge tubes with numbers without anticoagulation for serum separation and detection of PRRSV-specific antibodies; the other 5 ml of anterior vena cava blood was quickly injected into the corresponding numbered sodium heparin anticoagulation tubes, and inverted several times to allow the blood to fully contact with the sodium heparin in the tube to prevent coagulation, which was used for the separation of peripheral blood lymphocytes.
[0037] 3.3 Evaluation method The separated serum was used to detect the immune IgG antibody titer by ELISA method, and PBMC was used for T cell typing test, cytokine transcription change test, in vitro lymphocyte proliferation test, and cytokine concentration test to evaluate the humoral immunity and cellular immunity levels of the recombinant African swine fever bivalent vaccine.
[0038] 1 Methods: Dilute the purified P72 protein to 1 μg / ml with 50 mmol / L CBS (pH 9.6), add 100 μl to each well of a 96-well ELISA plate, and coat overnight at 4°C. After washing three times with PBST, block with 5% horse serum (PBS buffer system) at 37°C for 1 hour. After washing three times, serum samples were diluted with blocking solution (5% horse serum, PBS buffer system) at a ratio of 1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12800, 100 μl was added to each well, two replicates were added, and incubated at 37°C for 1 hour; after washing three times, HRP-labeled rabbit anti-pig IgG diluted to 1:10000 was added to each well, and incubated at 37°C for 1 hour; after washing three times, 50 μl TMB substrate was added to each well, and the reaction was carried out at room temperature, away from light, for 10 minutes, and 2M H2SO4 was added to stop the reaction. The absorbance value OD was read at a wavelength of 450 nm. 450 .
[0039] 2 Results like Figure 6 As shown in the figure, compared with the control group, the recombinant African swine fever bivalent vaccine immunization group can stimulate a higher level of antibody immune response. One week after the first immunization, the antibody titer was less than 1:100. Two weeks after the first immunization, the increase in antibody titer in the recombinant African swine fever bivalent vaccine group was significantly higher than that in the control group, and the antibody titer continued to increase thereafter. By the end of the experiment, the antibody titer of the immunized pigs was higher than 1:3200.
[0040] The serum of the experimental animals was collected by conventional methods, and the IFNγ concentration of the collected serum was tested according to the instructions of the sheep anti-swine IFNγ ELISA test kit. The results showed that after vaccination, as the immunization time increased, the IFNγ concentration continued to rise, and remained at a high concentration for 4 weeks after immunization. At the end of the experiment, the IFNγ concentration of the experimental animals in the recombinant African swine fever bivalent vaccine immunization group was significantly higher than that of the control group (see Figure 7 ).
[0041] The levels of IL-4, IL-6, IL-10, and TNF- in serum were detected according to the procedure of the kit at days 0, 7, 14, 21, 28, 35, and 42 after the primary immunization. The cytokine concentration of each sample was expressed as the mean of three samples, while the cytokine mass of each group at the designated time point was calculated as the mean ± standard deviation (SD) of five piglets.
[0042] To detect cytokines secreted by activated PBMCs of piglets in lymphocyte proliferation assays, PBMCs of immunized piglets were stimulated with purified antigens, and 72 hours later, the supernatants were evaluated by quantitative ELISA. Compared with the control group, PBMC TNF and IL-10 in the immunized group were significantly different seven days after immunization (P<0.05), and PBMC TNF, IL-4, IL-6, and IL-10 in the immunized group were extremely significantly different from those in the control group 14 days after immunization (see Figure 8 to Figure 11 ). This indicates that the recombinant African swine fever bivalent vaccine can stimulate a good cellular immune response.
[0043] 1. Isolation of PBMC Porcine PBMCs were isolated from fresh venous blood and anticoagulated with 5 mM heparin. The leukocyte layer was collected by centrifugation at 1500 rpm at 37°C for 30 min. PBMCs were washed twice with 15 ml of Hanks balanced saline and resuspended in RPMI medium supplemented with 5% fetal calf serum (Life Technologies, Gaithersburg, MD), 100 U / ml penicillin (Sigma), 100 mg / ml streptomycin (Sigma), 100 U / ml gentamicin (Sigma), 4 mM L-glutamate (Sigma), 1 mM sodium pyruvate (Life Technologies), 10 mM MEM non-essential amino acids (Life Technologies), and 250 mM 2-mercaptoethanol (Sigma).
[0044] 2. ELISPOT to determine the frequency of IFNγ-SC in PBMC 2.1 The extent of antigen-specific cellular immune responses in animals of different immunization groups and control groups was quantified by IFNγ ELISPOT (see Zuckermann et al., 1999 for the method). Peripheral blood mononuclear cells were diluted to a concentration of 5×10 6 / mL, take 100μl of cell suspension and spread it in the ELISPOT plate wells. Add ASFV (type I), ASFV (type II) inactivated antigen control wells, ConA stimulation wells as positive control wells, negative control wells, background control wells, and all samples are set up with 3 replicate wells.
[0045] 2.2 Culture the treated cells in a 37°C, 50% CO2 incubator for 24 hours (12 to 48 hours) (Note: the culture time can be extended to 30 hours depending on the situation; to ensure the accuracy of the data, the incubator and the ELISA plate must be in a completely static state during the entire cell culture process, and avoid moving or shaking the plate. At the same time, take measures to avoid evaporation, such as wrapping the ELISA plate with aluminum foil).
[0046] 2.3 PBMC were exposed to antigens for 2 hours at 37°C in a CO2 environment. The cells were removed by washing 6 times with PBST (0.05% Tween20). An appropriate amount of biotin-labeled detection antibody (P2C11-biotin) was taken, and the detection antibody was diluted to a concentration of 0.5 μg / mL with PBS containing 0.5% FCS. 100 μl was added to each well, and the plate was incubated at room temperature for 2 hours. The liquid in the wells after incubation was discarded, and the plate was washed 5 times with PBS, each time for 10 minutes. An appropriate amount of HRP-labeled streptavidin (Streptavidin-HRP Phosphase) was taken, and it was diluted 1000 times with PBS-0.5% FCS, and 100 μl was added to each well. The plate was incubated at room temperature for 1 hour. The liquid in the wells after incubation was discarded, and the plate was washed 5 times with PBS, each time for 10 minutes. Add 100 μl of ready-to-use TMB substrate solution to each well and incubate at room temperature in the dark for 15 to 45 minutes until spots are formed at the bottom of the wells (20 to 25 spots, about 25 minutes). Rinse the wells with double distilled water to terminate the color reaction. Dry at room temperature. Analyze the number of spot-forming cells (SFC) in each well using an ELISPOT analyzer or under a dissecting microscope. Record the results using spot-forming units: IFNgamma SFC / well, where each spot represents a cell that secretes IFNgamma.
[0047] 2.4 Positive judgment criteria: Stimulation index = IFNgamma-SFC per well after sample stimulation / IFNgamma-SFC per well after blank stimulation ≥ 2.1. Specific IFNγ-producing cells are determined by counting the number of blue dots.
[0048] In order to evaluate the development of specific regulatory immune responses caused by immunization with a recombinant African swine fever bivalent vaccine, IFNγ production was detected in PBMCs isolated from experimental animals before and after immunization. In this test, the presence of IFNγ-SC in unstimulated cultures represents the spontaneous background production of nonspecific cytokines. The frequency of IFNγ-SC caused by PBMC cultures stimulated with memory antigens is higher than the background product, indicating the production of virus-specific IFNγ-SC. The average values of the frequency of specific (memory antigen-stimulated) production and spontaneous (background) IFNγ-SC in each group during the entire experimental period (0 to 42 days) are shown in Fig.12 , Fig.13 . In the animals immunized with the recombinant protein vaccine, negligible IFNγ-producing cells were detected in the control group 42 days after immunization, ignoring the appearance of memory antigens in cell culture. All vaccine groups produced high levels of spontaneous cell secretion of IFNγ (range: 20-50 IFNγ-SC / 10 6PBMC). There was a significant difference between the unstimulated group and the control group (P < 0.01), indicating that the recombinant African swine fever bivalent vaccine can stimulate specific regulatory immune response.
[0049] Anticoagulated blood was collected on days 0, 7, 14, 21, 28, 35, and 42 after immunization, peripheral blood lymphocytes were separated, total lymphocyte RNA was extracted, and real-time fluorescence quantitative RT-PCR was used to detect the mRNA transcription levels of IL-17, TGF-β, and IFN-γ in peripheral blood. The reaction system (20L system) was as follows: cDNA 1.0μL, upstream and downstream primers 0.5μL each, 2XSYBR® Premix Ex Taq™ 10.0μL, RNase-free H0 8.0μL. Reaction procedure: 94℃3 min, 94℃20s, annealing temperature 20s, 72℃20s, 40 cycles.
[0050] The IL-17 gene mRNA transcription level reached a peak value in the immunized group 14 to 21 days after immunization (P<0.05). The immunized group stimulated the body to produce the immune regulatory factor IL-17 at a higher level than the control group, and then each group gradually returned to normal values; TGF-β mRNA transcription level, except for the immunized group, which increased significantly 7 days after immunization and formed a significant difference with the control group (P<0.05), there was no statistical difference in TGF-β mRNA transcription level between the immunized groups during the entire experimental period. IFN-γ mRNA transcription level, the immunized group increased significantly and reached a peak value 7 days after immunization, and was significantly higher than the control group from 7 days to 21 days after immunization. By 42 days after immunization, the PBMC cytokine IL-17, TGF-β and IFN-γ transcription levels of all immunized groups were not significantly different from those of the control group (P﹥0.05). The results show that the recombinant African swine fever bivalent vaccine can produce relatively stronger cellular immunity and nonspecific immune response ( Figure 14 to Figure 16 ).
[0051] The number of CD3+, CD3+CD4+, CD3+CD8+ positive cells and the CD4+ / CD8+ ratio of separated PBMCs were detected by flow cytometry among 10,000 cells.
[0052] 1. Reagent preparation Fluorescent washing solution: PBS containing 5% calf serum. Introduce calf serum into 450 ml of PBS, mix well and make up to 500 ml, filter and sterilize with 0.22 μm filter membrane, and store at -20°C for later use.
[0053] Fluorescence preservation solution: 100 ml 0.15M PBS pH7.4, 2% glucose, 1% formaldehyde, 0.1% NaN3, sterilized by filtration with 0.22μm filter membrane, and stored at -20℃ for future use.
[0054] 2 Type operation Take 1×10 6 Transfer the porcine lymphocytes into 1.5ml centrifuge tubes with corresponding numbers, centrifuge at 1500rpm for 5 minutes with 1ml fluorescent washing solution, discard the supernatant, and resuspend the cells with 100μl fluorescent washing solution; add 1-5μl (the specific volume is subject to the results determined in the preliminary experiment or the dosage recommended by the manufacturer) APC-CD3 (about 0.5μg), AlexaFlupr-CD8 (about 0.125μg) and PE-CD4 (0.25μg) fluorescent antibodies (Note: it is best to avoid light when adding fluorescently labeled monoclonal antibodies), mix thoroughly and place at 4℃ away from light for 30 minutes. At the same time, set up 4 blank control tubes and add 2μl PBS, APC-CD3, AlexaFlupr-CD8 (about 0.125μg) and PE-CD4 (0.25μg) fluorescent antibodies respectively. Flupr-CD8 and PE-CD4 were washed twice with fluorescent washing solution, 1 ml each time, centrifuged at 1500 rpm for 5 minutes, and the supernatant was discarded; the cells at the bottom of the tube were resuspended with 200 μl (200-500 μl) fluorescent preservation solution, and the number of CD3+, CD3+CD8+, CD3+CD4 positive cells and CD4+CD8+ ratio in 10,000 cells were detected by flow cytometry (the number of cells in each sample must reach 10 6 The samples should not be stored for too long and should be tested as soon as possible to prevent the green fluorescence signal from weakening).
[0055] 3 Results The results of cellular immunity level detection showed that a certain cellular immune response could be induced 7 days after immunization, and the induced cellular immune response was enhanced after the second immunization.
[0056] 3.1 Changes in the proportion of CD3+ subsets in peripheral blood lymphocytes From 14 days to 35 days after immunization, the proportion of CD3+ subpopulation in peripheral blood lymphocytes of some piglets in the immunization group was significantly higher than that in the control group (P<0.05). Before immunization, 7 days after immunization, and 42 days after immunization, there was no significant difference in the proportion of CD3+ subpopulation in peripheral blood lymphocytes between the immunization group and the control group (P>0.05). Fig.17 ).
[0057] 3.2 Changes in the proportion of CD3+CD4+ subsets in peripheral blood lymphocytes Before immunization, there was no significant difference in the proportion of CD3+CD4+ subpopulations in peripheral blood lymphocytes between the immunization group and the control group (P﹥0.05). After immunization, the proportion of CD3+CD4+ subpopulations in the peripheral blood lymphocytes of the vast majority of piglets in the immunization group showed a significant difference from that in the control group (P<0.05). Fig.18 ).
[0058] 3.3 Changes in the proportion of CD3+CD8+ subsets in peripheral blood lymphocytes Before immunization and 42 days after immunization, there was no significant difference in the proportion of CD3+CD8+ subpopulations in peripheral blood lymphocytes between the immunized group and the control group (P﹥0.05). From 7 to 35 days after immunization, the proportion of CD3+CD8+ subpopulations in peripheral blood lymphocytes of most piglets in the immunized group was significantly higher than that in the control group (P<0.05). Fig.19 ).
[0059] 3.4 Changes in the ratio of CD4+ to CD8+ subsets in peripheral blood lymphocytes During the entire experimental period, except for a few pigs, there was no significant difference in the CD4 / CD8+ subpopulation ratio in peripheral blood lymphocytes between the immunization group and the control group (P>0.05) ( Fig. 20 ).
Claims
1. A recombinant African swine fever bivalent vaccine fusion protein, characterized in that: Its amino acid sequence is shown as SEQ ID No. 2 in the sequence listing.
2. A nucleic acid molecule encoding the fusion protein according to claim 1, characterized in that: The gene sequence is shown as SEQ ID No. 1 in the sequence table. A vector comprising the nucleic acid molecule according to claim 2. A host cell comprising the vector according to claim 3.
5. A recombinant African swine fever bivalent vaccine, characterized in that: Contains the fusion protein according to claim 1.
6. A preparation method, characterized in that: The recombinant African swine fever bivalent vaccine according to claim 5 is prepared, and its preparation process includes but is not limited to the construction of prokaryotic expression and eukaryotic expression fermentation process systems, the establishment of affinity, reverse, hydrophobic, ion exchange and other purification processes, and the establishment of an emulsification process.
7. Use of the recombinant African swine fever bivalent vaccine according to claim 5 in preventing African swine fever.
